Código QR (código de barras bidimensional)

Targeting ERBB2 mutations in solid tumors: biological and clinical implications

Abstract Preclinical data have shown that ERBB2 activating mutations are responsive to HER2 tyrosine kinase inhibitors. The aim of this study is to characterize the landscape of ERBB2 mutations in solid tumors and the potential efficacy of ERBB2 targeting. We analyzed the next-generation sequencing...

ver descrição completa

Na minha lista:
Principais autores: Sophie Cousin, Emmanuel Khalifa, Amandine Crombe, Yech’an Laizet, Carlo Lucchesi, Maud Toulmonde, Sylvestre Le Moulec, Céline Auzanneau, Isabelle Soubeyran, Antoine Italiano
Formato: Artigo
Idioma:Inglês
Publicado em: BMC 2018-06-01
coleção:Journal of Hematology & Oncology
Assuntos:
ERBB2
Mutation
Targeted therapy
Secondary resistance
Acesso em linha:http://link.springer.com/article/10.1186/s13045-018-0630-4
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados